Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

New PDE5 inhibitors in early development at Pfizer

Nov. 13, 2002

Series of PDE5 inhibitors in early development at Tanabe Seiyaku

Nov. 11, 2002

Potential of GPI-1046 for maintaining erectile function after radical prostatectomy

Nov. 6, 2002

Prostanoid IP antagonists and their use in bladder disorders reported by Roche

Nov. 6, 2002

Tadalafil reported safe and effective in broad-spectrum erectile dysfunction

Nov. 5, 2002

TAP Pharmaceutical submits NDA for Uprima for ED

Nov. 4, 2002

Promising laboratory results for phosphate-lowering RenaZorb

Nov. 4, 2002

Keryx extends international manufacturing and negotiating rights for KRX-101

Oct. 30, 2002

A-278637: enhanced bladder selectivity and potency as compared to other KCOs

Oct. 29, 2002

FDA accepts Oxytrol NDA for filing

Oct. 29, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...